# GIMAN Performance & Dissertation Defense Readiness Review

**Date:** 2026-02-07
**Reviewer:** Automated Deep Code Review
**Repository:** GIMAN (Graph-Informed Multimodal Attention Network)
**Scope:** SOTA alignment, >90% AUC performance validation, dissertation defense readiness

---

## EXECUTIVE SUMMARY

GIMAN is a multi-phase research pipeline for Parkinson's Disease (PD) prognostic analysis using PPMI data, combining Graph Neural Networks, attention mechanisms, neuro-fuzzy inference, and digital twin simulation. The project has **ambitious scope and mature infrastructure** (~18K LOC, 365 Python files, 316 functions, 40+ documentation files) but faces **critical validation gaps** that separate reported internal metrics from defensible, generalizable performance claims.

### Verdict at a Glance

| Dimension | Status | Score |
|-----------|--------|-------|
| Architecture & SOTA Techniques | Strong | 8/10 |
| Internal Classification (PD vs HC) | Inflated | 4/10 |
| Survival/Progression Prediction | Failing | 2/10 |
| External Validation | Near-Random | 2/10 |
| Statistical Rigor | Incomplete | 4/10 |
| Explainability Framework | Good w/ Gaps | 7/10 |
| Digital Twin | Preliminary | 5/10 |
| Reproducibility | Moderate | 5/10 |
| **Overall Defense Readiness** | **Conditional** | **4.5/10** |

---

## 1. CURRENT PERFORMANCE: WHAT THE NUMBERS ACTUALLY SAY

### 1.1 Classification Task (PD vs Healthy Control)

| Model | Dataset | AUC-ROC | Accuracy | Notes |
|-------|---------|---------|----------|-------|
| GIMAN v1.1.0 | 297 PPMI (internal) | **99.88%** | 97.0% | 12 features; no external validation |
| GIMAN v1.0.0 | PPMI (internal) | **98.93%** | — | 7 biomarkers; internal split only |
| Phase 9 Multi-task NF | PPMI (internal) | **98.16%** | 91.0% | SAA classification; 7-patient concern |
| Phase 9 Full NF | PPMI (internal) | **96.83%** | 91.0% | Neuro-fuzzy variant |

**Critical Problem:** These numbers look exceptional but are **misleading for several reasons:**

1. **Feature leakage suspicion:** The v1.1.0 model includes `NHY` (Hoehn & Yahr stage, t=22.04) and `NP3TOT` (MDS-UPDRS Part III total, t=17.92) as features. These are **direct clinical indicators of PD severity** — including them in a PD-vs-HC classifier is circular reasoning. NHY alone nearly perfectly separates PD from HC. Removing these two features would likely drop AUC dramatically.

2. **Sample size vs. parameter count:** Phase 9 models report >96% AUC but operate on datasets as small as 7 patients with 500K+ parameters — a parameter-to-sample ratio of ~71,000:1, which virtually guarantees memorization.

3. **No nested cross-validation:** Hyperparameters were tuned using information from the same data used for final evaluation, introducing optimistic bias.

### 1.2 Survival/Progression Prediction

| Model | Dataset | Metric | Value | Notes |
|-------|---------|--------|-------|-------|
| Phase 8 Best | PPMI Prodromal | C-index (test) | 0.9666 | Artifact-backed; tiny dataset |
| Phase 8 CV Mean | PPMI Prodromal | C-index (CV) | 0.8445 | More realistic |
| Week 4 Progression | 88 train / 20 test | C-index (test) | **0.38** | Below random (0.5) |
| Week 4 Conversion | 88 train / 20 test | AUC (test) | **0.64** | Val was 0.85; gap = -0.21 |

**Critical Problem:** The progression model performs **worse than random** on test data (C-index = 0.38). The conversion model drops from 0.85 validation to 0.64 test AUC. These are hallmarks of severe overfitting.

**Root Cause (documented in TODO.md):**
- Motor R² = **-94.08** (predictions worse than predicting the mean)
- Cognitive AUC = **0.59** (barely above random)
- 1,536 NaN values in temporal embeddings
- 500K+ parameters trained on 7 patients

### 1.3 External Validation

| Cohort | N | AUC | PR-AUC | ECE | Status |
|--------|---|-----|--------|-----|--------|
| Phase 6 PPMI "external-like" | 247 | 0.45 | — | — | Worse than random |
| PPMI External (Feb 2026) | 90 | **0.59** | 0.29 | 0.39 | Barely above random |
| Phase 8 Survival External | — | FAILED | — | — | Feature dimension mismatch |

**Critical Problem:** External validation shows the model **does not generalize**. An AUC of 0.59 on 90 external patients means the model has near-zero discriminative ability outside its training distribution.

### 1.4 Baseline Comparisons (SOTA Internal Lock)

| Baseline | AUC | PR-AUC | Brier | ECE |
|----------|-----|--------|-------|-----|
| Logistic Regression | 0.47 | 0.17 | 0.27 | 0.34 |
| Random Forest | 0.46 | 0.17 | 0.24 | 0.31 |
| SVM-RBF | 0.54 | 0.23 | 0.15 | 0.003 |

**Problem:** All baselines perform at or below random. This suggests the canonical survival/progression task as currently formulated may have **fundamental signal-to-noise issues** — either the features lack predictive power for this specific endpoint, the labels are noisy/synthetic, or the preprocessing pipeline corrupts the signal.

---

## 2. ARCHITECTURE & SOTA ALIGNMENT

### 2.1 Techniques Implemented

| Technique | Status | SOTA Relevance |
|-----------|--------|----------------|
| Graph Attention Networks (GAT) | Implemented | Current standard for graph ML |
| Multi-head attention (4 heads) | Implemented | Standard practice |
| Residual connections | Implemented | Standard practice |
| Batch/Layer normalization | Implemented | Standard practice |
| Focal loss for imbalance | Implemented | Good for medical data |
| Neuro-fuzzy inference (Takagi-Sugeno) | Implemented | Novel for PD prognosis |
| Variational Autoencoder (heterogeneity) | Implemented | Standard for subtyping |
| Cox partial likelihood loss | Implemented | Standard survival analysis |
| SHAP explainability | Implemented | Standard XAI |
| Digital twin simulation | Implemented | Emerging; preliminary |
| Spectral normalization | Not implemented | Would improve GAN stability |
| Transformer/self-attention backbone | Not implemented | Current SOTA for sequences |
| Contrastive learning | Not implemented | SOTA for representation learning |
| Foundation model fine-tuning | Not implemented | Emerging SOTA |

### 2.2 Architecture Strengths
- The **neuro-fuzzy hybrid** (Phase 9) is a genuine novel contribution — combining differentiable Takagi-Sugeno inference with GNN embeddings is uncommon in PD research
- The **multi-task architecture** (joint SAA classification + survival prediction) is well-motivated
- Parameter efficiency is good for the neuro-fuzzy variant (~12K params)
- The patient similarity graph construction from multimodal biomarkers is well-designed

### 2.3 Architecture Weaknesses
- The GIMANBackbone is a **3-layer GraphConv** (~30K params) — functional but not architecturally novel
- No transformer-based components despite their dominance in recent medical AI
- Spatiotemporal embeddings (CNN3D + GRU, 256-dim) generate 1,536 NaN values, suggesting the imaging pipeline is non-functional
- The survival GAT has 152K parameters but trains on <100 patients

---

## 3. VALIDATION METHODOLOGY ASSESSMENT

### 3.1 What IS Implemented

| Method | Implementation | Quality |
|--------|---------------|---------|
| Stratified K-Fold CV (k=5) | evaluator.py | Correct |
| Patient-level split disjointness | benchmark.py:59-61 | Correct |
| Bootstrap 95% CI (500 iterations) | metrics.py | Correct |
| Early stopping (patience=10-25) | trainer.py | Correct |
| Class weight balancing | trainer.py | Correct |
| ECE / Brier score / calibration | metrics.py | Correct |
| McNemar's test, Cohen's kappa | documented | Correct |

### 3.2 What is MISSING (Critical)

| Method | Status | Impact |
|--------|--------|--------|
| **LOOCV for small datasets** | Planned in TODO.md; never deployed | Cannot validate 7-patient results |
| **Nested cross-validation** | Not implemented | Hyperparameter selection biases AUC upward |
| **Temporal validation split** | Not implemented | No protection against temporal leakage |
| **Proper external validation** | AUC = 0.59; effectively failed | Cannot claim generalizability |
| **Preprocessing within CV folds** | Not implemented | Imputation/scaling on full data before split = leakage |
| **Imputation holdout validation** | In-sample only (R² ≈ 0.9 is on training data) | Imputation quality claims are invalid |
| **Subgroup robustness analysis** | Not implemented | No sex/age/severity stratification |
| **Multiple testing correction** | Not implemented | Inflated significance when many metrics reported |
| **Feature importance stability across folds** | Not implemented | SHAP values may be unstable |
| **Data/split hash locking** | Not implemented | Reproducibility not guaranteed |

### 3.3 Data Integrity Issues

1. **Synthetic label contamination:** Phase 8 training scripts generate synthetic survival labels when real labels are unavailable, but documentation claims "100% real data"
2. **Cohort size drift:** Documentation claims 350 patients at 60% threshold; actual artifact shows 23 patients
3. **Root path bugs:** `phase8/prepare_final_pyg_data.py` uses `parents[2]` which resolves to wrong directory
4. **Survival label schema inconsistency:** Three different naming conventions across pipeline stages (event_time/event_observed → time_to_event/phenoconverted → time/event) with no schema validation

---

## 4. PATH TO >90% AUC (LEGITIMATE)

The current 99.88% AUC on PD-vs-HC classification is **not credible** due to feature leakage (NHY, NP3TOT). Here is what legitimate >90% AUC requires:

### 4.1 For PD Classification (achievable)
1. **Remove leaky features:** Drop NHY and NP3TOT; they are PD diagnostic criteria
2. **Use only pre-diagnostic biomarkers:** LRRK2, GBA, APOE, pTau, tTau, UPSIT, Alpha-Synuclein, DAT-SPECT
3. **Implement nested CV:** Inner loop for hyperparameters, outer loop for performance
4. **Target:** AUC > 0.85 on biomarker-only features would be a strong result
5. **External cohort validation:** Must hold up on PDBP, ICEBERG, or temporally-held-out PPMI

### 4.2 For Survival/Progression (requires major work)
1. **Fix the data pipeline:** Resolve 1,536 NaN values in temporal embeddings
2. **Increase effective sample size:** Currently 7 patients for some tasks — need 50+ events minimum
3. **Use proper survival evaluation:** Time-dependent AUC, not just concordance index
4. **Target:** C-index > 0.65 on external data would be competitive; current 0.38 is failing
5. **Remove synthetic label fallback:** All training must use real endpoints only

### 4.3 For SAA Classification (most promising path)
1. Phase 9 neuro-fuzzy SAA AUC of 0.98 needs validation on held-out data
2. If it holds under LOOCV or proper external validation, this is a strong result
3. The neuro-fuzzy interpretability angle strengthens the contribution
4. **Must demonstrate** this isn't driven by the same leaky features

---

## 5. EXPLAINABILITY & DIGITAL TWIN ASSESSMENT

### 5.1 Explainability: GOOD (7/10)
**Strengths:**
- Multi-method approach: SHAP + attention weights + GNNExplainer + counterfactuals
- Modality ablation analysis (spatial/genomic/temporal importance)
- Calibration analysis with Platt and isotonic regression
- Publication-quality visualizations (7 IEEE figures)

**Gaps:**
- SHAP uses only 20 background samples — insufficient for clinical claims
- GNNExplainer implementation is generic; Phase 6 task-specific results may be missing
- Low counterfactual success rate (3.3%) undermines intervention recommendations
- Attention analysis has fallback to dummy values (0.33, 0.33, 0.34) without flagging
- Feature importance not validated for stability across CV folds

### 5.2 Digital Twin: PRELIMINARY (5/10)
**Strengths:**
- Clean architecture with dataclasses and type hints
- Uncertainty quantification with confidence bands
- Sensitivity analysis across patients and interventions
- Temperature-scaled risk calculation

**Gaps:**
- Scaling factors (0.25 and 0.4) are ad-hoc with no derivation or validation
- Only 2 intervention features tested (UPDRS_I, SCOPA_AUT_SCORE)
- No validation against actual longitudinal outcomes
- No comparison to published PD progression curves
- Marked as "v1 approximation" in comments — not production-grade

---

## 6. DISSERTATION DEFENSE READINESS

### 6.1 What WILL Survive Committee Scrutiny

1. **Problem formulation:** PD prognosis using multimodal data is important and well-motivated
2. **Architecture design:** GNN + neuro-fuzzy hybrid is a genuine contribution
3. **Pipeline engineering:** 18K LOC production pipeline demonstrates technical competence
4. **Explainability framework:** Multi-method XAI approach is thorough
5. **Data integration:** 7+ biomarker modalities with proper PPMI data handling
6. **Documentation:** 40+ markdown files show systematic development

### 6.2 What WILL NOT Survive Committee Scrutiny

1. **"99.88% AUC" claim:** Committee will immediately identify NHY/NP3TOT as leaky features. This claim must be retracted or re-evaluated without diagnostic features.

2. **Progression model performance:** C-index = 0.38 and Motor R² = -94.08 cannot be presented as results. These must either be fixed or honestly reported as negative results with analysis of why.

3. **External validation:** AUC = 0.59 on 90 patients demonstrates the model does not generalize. A committee will ask: "If your model doesn't work on external data, what exactly is your contribution?"

4. **Sample size for survival:** Training on 7 patients with 500K parameters is indefensible. The committee will ask about statistical power and memorization.

5. **Synthetic data transparency:** If any training used synthetic labels while documentation claims otherwise, this is a scientific integrity issue.

6. **Digital twin clinical validation:** Ad-hoc scaling factors without derivation will be questioned.

### 6.3 Likely Committee Questions

1. "Your PD classifier includes Hoehn & Yahr stage as a feature. Isn't that the diagnosis itself?"
2. "Your test set C-index is 0.38 — worse than random. How do you explain that?"
3. "Your external validation AUC is 0.59. What evidence do you have that this model works?"
4. "You trained on 7 patients with 500K parameters. How is this not memorization?"
5. "Your TODO.md documents a 'severe overfitting crisis.' Has this been resolved?"
6. "Can you reproduce your Phase 6 GNNExplainer results right now?"
7. "Your digital twin uses scaling factors of 0.25 and 0.4. Where do these come from?"

---

## 7. ACTIONABLE REMEDIATION PLAN

### Priority 0: MUST DO (blocks defense)

| # | Action | Files Affected | Goal |
|---|--------|---------------|------|
| 1 | Remove NHY, NP3TOT from classification features; re-evaluate AUC | training/models.py, data_processing/ | Honest AUC without leaky features |
| 2 | Implement LOOCV for small-sample tasks (n < 30) | training/evaluator.py | Credible small-sample validation |
| 3 | Fix temporal embedding NaN crisis (1,536 values) | spatiotemporal_embeddings.py | Functional imaging pipeline |
| 4 | Run nested CV: inner for hyperparams, outer for evaluation | training/optimize_binary_classifier.py | Unbiased performance estimates |
| 5 | Audit and remove synthetic label fallbacks | Phase 8 training scripts | Scientific integrity |
| 6 | Reconcile cohort documentation with actual data | Docs/, data manifests | Accurate reporting |

### Priority 1: SHOULD DO (strengthens defense)

| # | Action | Goal |
|---|--------|------|
| 7 | Run proper external validation on PPMI held-out temporal split | Generalizability evidence |
| 8 | Implement preprocessing-within-folds (impute/scale inside CV) | Eliminate preprocessing leakage |
| 9 | Add subgroup analysis (sex, age bands, severity) | Robustness evidence |
| 10 | Validate SHAP stability across CV folds | Explainability robustness |
| 11 | Add derivation/validation for digital twin scaling factors | Digital twin credibility |
| 12 | Generate reproducibility manifest (data hashes, split hashes, code versions) | Reproducibility guarantee |

### Priority 2: WOULD STRENGTHEN (differentiators)

| # | Action | Goal |
|---|--------|------|
| 13 | Implement contrastive learning for patient embeddings | SOTA alignment |
| 14 | Add time-dependent AUC for survival evaluation | Modern survival metrics |
| 15 | Create integrated explainability→digital twin pipeline | Novel contribution |
| 16 | Compare against published PD prediction benchmarks | Literature positioning |
| 17 | Add Kaplan-Meier survival curves by risk quartile | Clinical interpretability |

---

## 8. HONEST ASSESSMENT: WHERE DOES GIMAN STAND?

### What GIMAN IS:
- A well-engineered, modular ML pipeline for PD research
- A novel architectural contribution (GNN + neuro-fuzzy hybrid)
- A comprehensive explainability framework with multi-method validation
- A strong demonstration of technical capability across 8+ development phases

### What GIMAN IS NOT (yet):
- A validated clinical prediction tool (external AUC = 0.59)
- A >90% AUC system on legitimate, non-leaky features (untested)
- A model that generalizes beyond its training distribution
- A system with sufficient sample size for its model complexity

### Recommended Dissertation Framing:
**"A Novel Graph-Informed Neuro-Fuzzy Framework for Multimodal Parkinson's Disease Prognosis: Architecture, Methodology, and Preliminary Validation"**

Frame as:
1. **Methodological contribution:** The GNN + neuro-fuzzy architecture and multi-method XAI framework
2. **Pipeline contribution:** End-to-end multimodal integration from raw PPMI to predictions
3. **Preliminary results:** Internal validation with honest reporting of external validation gaps
4. **Future work:** External validation, larger cohorts, clinical deployment pathway

Do NOT frame as:
- A clinically validated system
- A system achieving >90% AUC on legitimate features (until re-evaluated)
- A production-ready digital twin for patient simulation

---

## 9. SPECIFIC PERFORMANCE TARGETS FOR DEFENSE

| Task | Current | Minimum for Defense | Competitive Target | SOTA Reference |
|------|---------|--------------------|--------------------|----------------|
| PD Classification (clean features) | Unknown (99.88% with leaky features) | AUC > 0.80 | AUC > 0.85 | Biomarker-only models: 0.80-0.90 |
| SAA Classification | 0.98 (internal, unvalidated) | AUC > 0.75 (external) | AUC > 0.85 | Limited published benchmarks |
| Progression C-index | 0.38 (test) | C-index > 0.60 | C-index > 0.70 | DeepSurv PD: 0.65-0.75 |
| External Validation | 0.59 | AUC > 0.65 | AUC > 0.75 | Multi-site PD: 0.70-0.80 |
| Calibration (ECE) | 0.39 (raw) | ECE < 0.10 | ECE < 0.05 | Well-calibrated models: <0.05 |

---

## 10. CONCLUSION

GIMAN demonstrates **exceptional engineering ambition** and **genuine architectural novelty** in the neuro-fuzzy GNN space. However, the project's current performance claims are undermined by **feature leakage in classification**, **severe overfitting in progression prediction**, and **near-random external validation**.

The path to a defensible dissertation requires:
1. Honest re-evaluation of metrics without leaky features
2. Resolution of the overfitting crisis documented in TODO.md
3. At minimum, a temporal holdout validation showing meaningful discrimination
4. Reframing from "high-performance clinical system" to "novel methodology with preliminary validation"

The architectural and explainability contributions are strong enough to carry a dissertation — but only if the performance claims are corrected and honest limitations are front-and-center.
